260.91

5.11% -14.73

Krystal Biotech Inc (KRYS)

Overview News Price History Option Chain Financials Why KRYS Down? Discussions Forecast

Krystal Biotech Inc stock is traded at $260.91, with a volume of 132.56K. It is down -5.11% in the last 24 hours and down -7.34% over the past month. Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.

Previous Close:

$275.64

Open:

$267.6

24h Volume:

132.56K

Relative Volume:

0.45

Market Cap:

$7.63B

Revenue:

$290.51M

Net Income/Loss:

$89.16M

P/E Ratio:

87.26

EPS:

2.99

Net Cash Flow:

$119.18M

1W Performance:

-4.75%

1M Performance:

-7.34%

6M Performance:

+75.53%

1Y Performance:

+45.91%

1-Day Range:

$259.00

$270.00

1-Week Range:

$259.00

$277.03

52-Week Range:

$122.80

$298.30

Krystal Biotech Inc Stock (KRYS) Company Profile

Name

Krystal Biotech Inc

Sector

Healthcare (1114)

Industry

Biotechnology (620)

Phone

(412) 586-5830

Address

2100 WHARTON STREET, PITTSBURGH, PA

Employee

295

Twitter

@KrystalBiotech

Next Earnings Date

2024-11-04

Latest SEC Filings

KRYS's Discussions on Twitter

Compare KRYS vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
KRYS Krystal Biotech Inc	261.00	8.06B	290.51M	89.16M	119.18M	2.99
VRTX Vertex Pharmaceuticals Inc	488.26	126.21B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	785.75	82.64B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	756.41	47.46B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	325.86	44.15B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	310.77	35.08B	4.98B	69.60M	525.67M	0.5198

Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-06-26	Upgrade	Citigroup	Neutral → Buy
Mar-05-25	Initiated	Jefferies	Buy
Aug-06-24	Downgrade	Citigroup	Buy → Neutral
Nov-20-23	Initiated	Goldman	Buy
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight
Oct-12-23	Initiated	Citigroup	Buy
Sep-07-23	Initiated	Berenberg	Buy
Apr-18-23	Initiated	Stifel	Buy
Feb-28-23	Upgrade	Goldman	Neutral → Buy
Aug-25-22	Downgrade	Goldman	Buy → Neutral
Jan-18-22	Initiated	BofA Securities	Buy
Jul-20-21	Upgrade	Goldman	Neutral → Buy
Sep-18-20	Initiated	B. Riley FBR	Buy
Jun-04-20	Initiated	Evercore ISI	Outperform
Sep-24-19	Initiated	Goldman	Neutral
Aug-06-19	Reiterated	H.C. Wainwright	Buy
Jun-24-19	Reiterated	Chardan Capital Markets	Buy
Jun-24-19	Reiterated	H.C. Wainwright	Buy
May-30-19	Initiated	Guggenheim	Buy
Sep-11-18	Initiated	Cantor Fitzgerald	Overweight

View All

Krystal Biotech Inc Stock (KRYS) Latest News

Feb 28, 2026

Krystal Biotech (KRYS) Is Up 5.6% After Stronger 2025 Profitability And EPS Growth Has The Bull Case Changed? - Sahm

Feb 28, 2026

Guggenheim Lifts PT on Krystal Biotech (KRYS) to $284 From $224 - Yahoo Finance

Feb 28, 2026

Feb 26, 2026

Krystal Biotech director Janney sells shares worth $10.1 million - Investing.com

Feb 26, 2026

Krystal Biotech (NASDAQ:KRYS) Director Daniel Janney Sells 700 Shares - MarketBeat

Feb 26, 2026

Krystal Biotech (NASDAQ:KRYS) Director Daniel Janney Sells 37,895 Shares - MarketBeat

Feb 26, 2026

Daniel Janney Sells 7,741 Shares of Krystal Biotech (NASDAQ:KRYS) Stock - MarketBeat

Feb 26, 2026

Krystal Biotech Director Janney Daniel Sells Over $16 Million in Company Stock - TradingView

Feb 26, 2026

KRYS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Feb 26, 2026

Vanguard Group Inc. Cuts Stock Position in Krystal Biotech, Inc. $KRYS - MarketBeat

Feb 26, 2026

Assessing Krystal Biotech (KRYS) Valuation After Earnings Beat And Profitability Milestone - simplywall.st

Feb 26, 2026

Feb 25, 2026

(KRYS) Movement as an Input in Quant Signal Sets - Stock Traders Daily

Feb 25, 2026

Krystal Biotech (NASDAQ:KRYS) Given New $284.00 Price Target at Guggenheim - MarketBeat

Feb 25, 2026

Guggenheim Raises Price Target for Krystal Biotech (KRYS) to $284 | KRYS Stock News - GuruFocus

Feb 25, 2026

Feb 24, 2026

Krystal Biotech slips more than 2% even after Q4 earnings and revenue top estimates - MSN

Feb 24, 2026

Risk On: Can Krystal Biotech Inc weather a recessionJuly 2025 Market Mood & Growth Focused Entry Reports - baoquankhu1.vn

Feb 24, 2026

Insider Unloading: Dino A Rossi Sells Options, Realizes $5.04M - Benzinga

Feb 24, 2026

Krystal Biotech to Present at TD Cowen 46th Annual Health Care Conference - Bitget

Feb 24, 2026

Krystal Biotech’s KB707 RMAT Win Opens New Lung Cancer Chapter - Yahoo Finance

Feb 24, 2026

Feb 23, 2026

Krystal Biotech (NASDAQ:KRYS) Director Sells $4,953,719.50 in Stock - MarketBeat

Feb 23, 2026

Krystal Biotech (KRYS) director Rossi sells shares worth $4.95 million - Investing.com

Feb 23, 2026

Krystal Biotech (KRYS) director Rossi sells shares worth $4.95 million By Investing.com - Investing.com India

Feb 23, 2026

Director at Krystal Biotech (NASDAQ: KRYS) sells 18,950 shares - Stock Titan

Feb 23, 2026